Search results: (10000)
News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab
At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.
News Effect of Trifluridine/Tipiracil Combination Depending on Patient Prognosis
The results of the RECOURSE clinical study were published in 2015 and became an important basis for the approval of the trifluridine/tipiracil combination in the treatment of metastatic colorectal cancer (mCRC). The data obtained in this study were also subjected to several post-hoc analyses. One of these recently brought information on how patient prognosis affects the clinical outcomes of this treatment.
News Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients
A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal Cancer Medicine, focusing on aspects of ibrutinib therapy in real clinical practice. The authors evaluated the impact of dose modification or temporary interruption of the drug administration.
News Incidence of Allergic Diseases in Children Probably Unrelated to Air Pollution
A recently published extensive meta-analysis of 7 cohorts of children aged 4 and 8 from 5 European countries investigated the relationship between air pollution at the child's place of residence and the incidence of allergic eczema, rhinoconjunctivitis, or asthma.
News Study PLATON: romiplostim in patients with ITP in real clinical practice
Recently, the results of the PLATON study with romiplostim, which was conducted in Central and Eastern European countries including the Czech Republic, were published. It was an observational non-interventional cohort study from real practice, and romiplostim was used within its approved indication.
News Use of Targeted Therapy with Dupilumab in Patients with Allergic Diseases
Interleukins (IL) 4 and 13 play an important role in the pathogenesis of allergic diseases. Their blockade is therefore a suitable strategy for a number of these conditions. This is offered by the new monoclonal antibody dupilumab (Dupixent), which is approved for the treatment of atopic dermatitis, asthma with type 2 inflammation, and chronic rhinosinusitis with nasal polyposis. Studies are ongoing to evaluate its efficacy in other diseases where type 2 inflammation predominates.
News How to Communicate and Receive an Oncological Diagnosis
Communicating the truth about a patient's health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system only began to emphasize this aspect, that is, honest and open communication between doctor and patient, several years after the Velvet Revolution.
News Prophylaxis of Thromboembolism with Low-Molecular-Weight Heparins in Oncology Patients: Efficacy and Safety of Doses Adjusted According to Anti-Xa Activity
Oncological patients undergoing surgical procedures are observed to have a high risk of thromboembolic complications. Recommended prophylactic dosing of low-molecular-weight heparins (LMWH) is often associated with subprophylactic anti-Xa activity in high-risk patients. A recently published study evaluated the efficacy and safety of administering enoxaparin in doses adjusted according to the measured anti-Xa activity.
News Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC − Case Studies
Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.
News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function – clinical practice commentary
Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.
News Can NOACs 'Compete' with Well-Managed Warfarin Treatment? Retrospective Data from Swedish Registers
The efficacy and safety of new oral anticoagulants (NOACs) in stroke prevention in atrial fibrillation have been proven by numerous studies. The quality of warfarin treatment, assessed by the 'time in therapeutic range' (TTR), ranged between 55% and 65% in these studies. The work of Swedish authors provides a comparison of patients treated with NOACs to a group on warfarin whose average TTR reached 70%.
News Another Positive Effect of Diosmin − Influence on Oxidative Stress
Diosmin is an established drug in the therapy of chronic venous insufficiency. It is known to act through several different mechanisms. A study by Polish authors provides evidence of its ability to reduce oxidative stress.
News The Role of Probiotics in the Prevention of Childhood Infections
Although common acute respiratory and gastrointestinal infections are a part of childhood, they pose a significant burden on families and the healthcare and social care system. An unexpected role in their prevention can be played by the gut microbiome, specifically its support through certain probiotics. However, it is necessary to choose products supported by clinical studies.
News Incidence of Glaucoma or Suspected Glaucoma Within the First Year Post-Lensectomy in Children and Treatment Approach to These Patients
The aim of the study conducted by a team of authors from several American universities was to determine the approximate incidence of glaucoma or suspected glaucoma in children under 13 years old within the first year after lensectomy and to describe the management of care for these patients.
News Metformin in New European Guidelines for Treating Patients with Diabetes and Cardiovascular Disease
The position of metformin has changed in the guidelines for the treatment of prediabetes and type 2 diabetes in individuals with cardiovascular (CV) disease, issued by the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) in 2019. The 2019 EASD recommendations differ somewhat, thus we provide the following updated summary.
News How trends in sports evolve among hemophiliacs and to what extent they are limited by their disease
Historically, physical activity was generally not recommended for hemophiliacs; however, with evolving treatment options and prophylaxis as the gold standard of care for these patients, sports have become part of their lives in recent years. The Netherlands, traditionally supportive of sports, including for patients with chronic illnesses, presented the results of a survey on hemophilia and sports in a poster presentation at the 13th annual EAHAD congress in The Hague this February.
News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate
The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.
News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
News Persistence of Treatment with Secukinumab and Ixekizumab in Patients with Moderate to Severe Psoriasis
Although IL-17 targeted drugs are increasingly used in the treatment of moderate to severe psoriasis, we currently have limited data on patient persistence with these treatments.
News Meta-analysis of Incidence of Infusion Reactions to Anti-EGFR Antibodies in Patients with mCRC
The application of antibodies against the epidermal growth factor receptor (EGFR), administered in slow infusions mainly as part of the treatment for metastatic colorectal cancer (mCRC), may be accompanied by infusion reactions or hypersensitivity reactions.
News Chronic Thromboembolic Pulmonary Hypertension – Editorial
Belicová M. Chronic Thromboembolic Pulmonary Hypertension in a Regional Hospital. Vnitř Lék 2011; 57(2): 140–146.
News European Survey on Prophylactic Treatment of Chemotherapy-Induced Nausea and Vomiting Suggests Gaps in Practice and Ways to Improve
Using recommended guidelines for antiemetic prophylaxis can prevent chemotherapy-induced nausea and vomiting (CINV). Nurses play a significant role in administering prophylactic treatment for CINV. Therefore, a survey was conducted in 16 European countries among middle medical personnel to evaluate the use of recommended antiemetic prophylaxis in oncology practice and the obstacles to its administration.
News Initiation of Sacubitril/Valsartan After Acute Decompensation of Chronic Heart Failure: The Sooner, the Better
The recently published analysis of data from the extended open-label follow-up of participants in the PIONEER-HF study clearly pointed out the difference in outcomes and prognosis of patients, which is led by the initiation of the combined drug during hospitalization compared to its initiation shortly after discharge.
News Could candesartan counteract adverse intestinal changes induced by hypertension?
An experimental study published last year was the first to show that administration of candesartan may increase the tightness of epithelial junctions in the intestinal wall and positively affect the composition of the microflora. It expands the knowledge of recently described pathophysiological changes in the gut associated with hypertension.
News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy
Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.